(Q51816001)

13 April 2018

title

Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. (English)

1 reference

13 April 2018

1 reference

C Ferrario

1

1 reference

13 April 2018

A Davidson

2

1 reference

13 April 2018

N Bouganim

3

1 reference

13 April 2018

R Aloyz

4

1 reference

13 April 2018

L C Panasci

5

1 reference

13 April 2018

publication date

17 February 2009

1 reference

13 April 2018

published in

Annals of Oncology

1 reference

13 April 2018

volume

20

1 reference

13 April 2018

issue

4

1 reference

13 April 2018

page(s)

792-795

1 reference

13 April 2018

Care with intrathecal trastuzumab

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

Leptomeningeal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

Use of intrathecal trastuzumab in a patient with carcinomatous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP019

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP019

1 reference

13 April 2018

1 reference

13 April 2018